









市场行情
/
股票
/
nasdaq-tvgn
/

Tevogen Bio Holdings Inc

TVGN

0.380USD

-0.001-0.26%

收盘 12/19, 16:00（美东）报价延迟15分钟

74.95M总市值

亏损市盈率 TTM



Tevogen Bio Holdings Inc

0.380

-0.001-0.26%

概览公司财务分析

概览

公司

财务

分析

关于 Tevogen Bio Holdings Inc 公司

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

Tevogen Bio Holdings Inc简介



公司代码TVGN

公司名称Tevogen Bio Holdings Inc

上市日期Nov 04, 2021

CEOSaadi (Ryan)

员工数量18

证券类型Ordinary Share

年结日Nov 04

公司地址15 Independence Boulevard, Suite #210

城市WARREN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编07059

电话16468078832

网址https://tevogen.com/

公司代码TVGN

上市日期Nov 04, 2021

CEOSaadi (Ryan)

Tevogen Bio Holdings Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Kirti Desai

Chief Financial Officer

10.45M

+7.73%

Dr. Neal Flomenberg, M.D.

Chief Scientific Officer and Global R&D Lead

3.53M

+9.28%

Mr. Sadiq Khan

Chief Commercial Officer

1.17M

+20.63%

Mr. Jeffrey Feike

Independent Director

641.77K

-21.90%

Dr. Keow Lin (Lindee) Goh

Independent Director

313.92K

-27.65%

Ms. Susan M. Podlogar

Independent Director

253.92K

-41.48%

Dr. Ryan Saadi, M.D.

Chairman of the Board, Chief Executive Officer

Mr. Victor Sordillo

Independent Director

Dr. Curtis Patton

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Kirti Desai

Chief Financial Officer

10.45M

+7.73%

Dr. Neal Flomenberg, M.D.

Chief Scientific Officer and Global R&D Lead

3.53M

+9.28%

Mr. Sadiq Khan

Chief Commercial Officer

1.17M

+20.63%

Mr. Jeffrey Feike

Independent Director

641.77K

-21.90%

Dr. Keow Lin (Lindee) Goh

Independent Director

313.92K

-27.65%

Ms. Susan M. Podlogar

Independent Director

253.92K

-41.48%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Saadi (Ryan H)

62.67%

Patel (Manmohan)

6.72%

Desai (Kirti)

5.11%

Flomenberg (Neal)

1.78%

BlackRock Institutional Trust Company, N.A.

0.65%

其他

23.07%

持股股东

占比

Saadi (Ryan H)

62.67%

Patel (Manmohan)

6.72%

Desai (Kirti)

5.11%

Flomenberg (Neal)

1.78%

BlackRock Institutional Trust Company, N.A.

0.65%

其他

23.07%

股东类型

持股股东

占比

Individual Investor

78.18%

Investment Advisor

1.68%

Investment Advisor/Hedge Fund

0.74%

Research Firm

0.09%

Bank and Trust

0.02%

其他

19.27%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

115

5.02M

2.55%

-6.01M

2025Q2

119

160.27M

86.89%

+1.70M

2025Q1

118

155.00M

115.37%

-16.72M

2024Q4

153

163.30M

93.29%

-39.38M

2024Q3

144

166.12M

95.10%

-39.63M

2024Q2

138

166.33M

103.53%

-38.91M

2024Q1

118

165.09M

105.20%

-36.99M

2023Q4

105

14.20M

68.79%

-44.82M

2023Q3

104

15.77M

75.02%

-42.16M

2023Q2

101

9.09M

32.79%

-42.84M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Saadi (Ryan H)

124.99M

63.54%

-20.00K

-0.02%

Aug 15, 2025

Patel (Manmohan)

13.35M

6.79%

+2.43M

+22.26%

Apr 30, 2025

Desai (Kirti)

10.45M

5.31%

+750.00K

+7.73%

Jun 27, 2025

Flomenberg (Neal)

3.53M

1.8%

+300.00K

+9.28%

Jun 27, 2025

BlackRock Institutional Trust Company, N.A.

1.22M

0.62%

+573.09K

+88.87%

Jun 30, 2025

Khan (Sadiq)

1.17M

0.59%

+200.00K

+20.63%

Jun 27, 2025

The Vanguard Group, Inc.

1.09M

0.55%

+50.31K

+4.83%

Jun 30, 2025

Patton (Curtis L)

1.03M

0.52%

-180.00K

-14.88%

Apr 30, 2025

Feike (Jeffrey L)

641.77K

0.33%

-180.00K

-21.90%

Apr 30, 2025

Geode Capital Management, L.L.C.

542.02K

0.28%

+55.63K

+11.44%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

ProShares Ultra Nasdaq Biotechnology

0.01%

Invesco Nasdaq Biotechnology ETF

0.01%

iShares Micro-Cap ETF

Proshares Ultra Russell 2000

iShares Biotechnology ETF

ProShares Hedge Replication ETF

iShares Russell 2000 Growth ETF

iShares Russell 2000 Value ETF

ProShares UltraPro Russell2000

Global X Russell 2000 ETF

ProShares Ultra Nasdaq Biotechnology

占比0.01%

Invesco Nasdaq Biotechnology ETF

占比0.01%

iShares Micro-Cap ETF

占比0%

Proshares Ultra Russell 2000

占比0%

iShares Biotechnology ETF

占比0%

ProShares Hedge Replication ETF

占比0%

iShares Russell 2000 Growth ETF

占比0%

iShares Russell 2000 Value ETF

占比0%

ProShares UltraPro Russell2000

占比0%

Global X Russell 2000 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Tevogen Bio Holdings Inc的前五大股东是谁？



Tevogen Bio Holdings Inc 的前五大股东如下：
Saadi (Ryan H)持有股份：124.99M，占总股份比例：63.54%。
Patel (Manmohan)持有股份：13.35M，占总股份比例：6.79%。
Desai (Kirti)持有股份：10.45M，占总股份比例：5.31%。
Flomenberg (Neal)持有股份：3.53M，占总股份比例：1.80%。
BlackRock Institutional Trust Company, N.A.持有股份：1.22M，占总股份比例：0.62%。